IOL Chemicals & Pharmaceuticals Ltd
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]
It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]
- Market Cap ₹ 2,532 Cr.
- Current Price ₹ 86.3
- High / Low ₹ 108 / 57.5
- Stock P/E 25.0
- Book Value ₹ 57.5
- Dividend Yield 1.16 %
- ROCE 8.86 %
- ROE 6.13 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 51.6%
Cons
- Company has a low return on equity of 8.05% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
2,184 | 2,217 | 2,133 | 2,079 | |
1,925 | 1,991 | 1,902 | 1,877 | |
Operating Profit | 259 | 226 | 231 | 202 |
OPM % | 12% | 10% | 11% | 10% |
17 | 25 | 30 | 22 | |
Interest | 8 | 16 | 16 | 15 |
Depreciation | 43 | 46 | 63 | 72 |
Profit before tax | 225 | 189 | 182 | 138 |
Tax % | 25% | 26% | 26% | 27% |
168 | 139 | 134 | 101 | |
EPS in Rs | 5.71 | 4.74 | 4.58 | 3.44 |
Dividend Payout % | 14% | 17% | 22% | 116% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -2% |
TTM: | -3% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -17% |
TTM: | -25% |
Stock Price CAGR | |
---|---|
10 Years: | 25% |
5 Years: | 1% |
3 Years: | 4% |
1 Year: | 17% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 8% |
Last Year: | 6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Equity Capital | 59 | 59 | 59 | 59 |
Reserves | 1,334 | 1,449 | 1,553 | 1,629 |
44 | 80 | 33 | 117 | |
526 | 435 | 600 | 577 | |
Total Liabilities | 1,962 | 2,022 | 2,244 | 2,382 |
561 | 752 | 933 | 1,172 | |
CWIP | 105 | 90 | 101 | 21 |
Investments | 2 | 20 | 20 | 21 |
1,294 | 1,161 | 1,190 | 1,169 | |
Total Assets | 1,962 | 2,022 | 2,244 | 2,382 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
93 | 122 | 290 | 179 | |
-121 | -120 | -191 | -154 | |
-2 | -4 | -92 | 46 | |
Net Cash Flow | -29 | -2 | 6 | 70 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Debtor Days | 79 | 83 | 81 | 90 |
Inventory Days | 95 | 77 | 111 | 95 |
Days Payable | 95 | 74 | 123 | 112 |
Cash Conversion Cycle | 79 | 86 | 69 | 73 |
Working Capital Days | 78 | 86 | 76 | 79 |
ROCE % | 14% | 12% | 9% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
1d - Audio recording of Q4 & FY2025 earnings call shared by IOL Chemicals.
- Announcement under Regulation 30 (LODR)-Investor Presentation 2d
- Announcement under Regulation 30 (LODR)-Newspaper Publication 17 May
-
Announcement under Regulation 30 (LODR)-Change in Management
17 May - Approved FY25 audited results; re-appointed Joint MD; appointed secretarial auditor; scheduled 38th AGM on 22 Aug 2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16 May - Q4 FY25: Revenue ₹527.8 Cr, EBITDA ₹67.5 Cr; new paracetamol unit commissioned; China export approval secured.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
May 2025TranscriptNotesPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Mar 2021Transcript PPT
-
Dec 2020Transcript PPT
-
Nov 2020TranscriptNotesPPT
Business Segments